CTS2190 Phase I /II Clinical Study in Patients
NCT06224387
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
224
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Pancreatic Cancer
Non-small Cell Lung Cancer
Triple-negative Breast Cancer
Interventions
DRUG:
CTS2190 capsules
Sponsor
CytosinLab Therapeutics Co., Ltd.